arav20210806_8k.htm
false 0001513818 0001513818 2021-08-09 2021-08-09
 


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
WASHINGTON, D.C. 20549
 

 
FORM 8-K
 

 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 9, 2021
 

 
Aravive, Inc.
(Exact name of Registrant as Specified in Its Charter)
 

 
Delaware 001-36361 26-4106690
(State or Other (Commission (IRS
Jurisdiction of File Employer
Incorporation) Number) Identification
    No.)
                  
River Oaks Tower
3730 Kirby Drive, Suite 1200
Houston, Texas 77098
(Address of principal executive offices)
 
(936) 355-1910
(Registrants telephone number, including area code)
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading 
Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.0001 per share ARAV Nasdaq Global Select Market
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 


 
 

 
Item 7.01.   Regulation FD Disclosure.
 
On August 9, 2021, Aravive, Inc. (the “Company”) issued a press release announcing that it has dosed the first patient in the Phase 1b portion of its Phase 1b/2 trial of AVB-500 in combination with gemcitabine and nab-paclitaxel as a first-line treatment in patients with advanced or metastatic pancreatic adenocarcinoma. The Phase 1b portion of the clinical trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of AVB-500 in combination with gemcitabine and nab-paclitaxel.
 
In addition, the Company will be making several presentations to investors over the next several weeks. In connection with the presentations, the Company intends to discuss the investor presentation, which is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
 
The information in this Item 7.01 and in the press release furnished as Exhibit 99.1 and in the investor presentation furnished as Exhibit 99.2 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
 
The press release furnished as Exhibit 99.1 and investor presentation furnished as Exhibit 99.2 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.
 
The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosures.
 
Item 8.01.   Other Events. 
 
On August 9, 2021, the Company issued a press release announcing that it has dosed the first patient in the Phase 1b portion of its Phase 1b/2 trial of AVB-500 in combination with gemcitabine and nab-paclitaxel as a first-line treatment in patients with advanced or metastatic pancreatic adenocarcinoma. The Phase 1b portion of the clinical trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of AVB-500 in combination with gemcitabine and nab-paclitaxel.
 
 
Item 9.01.   Financial Statements and Exhibits.
 
(d) Exhibits.
 
The following exhibit is furnished to this Current Report on Form 8-K:
 
     
     
Exhibit
Number
 
Description
99.1
99.2
 
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Date: August 9, 2021
ARAVIVE, INC.
(Registrant)
 
     
     
 
By:
/s/ Gail McIntyre
 
 
Name:
Gail McIntyre
 
 
Title:
Chief Executive Officer
 
 
 
ex_272944.htm

Exhibit 99.1

 

https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-logo.jpg

 

Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma

 

 

Trial to Evaluate AVB-500 as a First-Line Treatment in Combination with Gemcitabine and Nab-Paclitaxel

 

Continues Expansion of AVB-500 in Multiple Oncology Indications and Combinations

 

 

Houston, TX, August 9, 2021 – Aravive Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced the Company has dosed the first patient in the Phase 1b portion of its Phase 1b/2 trial of AVB-500 in combination with gemcitabine and nab-paclitaxel as a first-line treatment in patients with advanced or metastatic pancreatic adenocarcinoma. The Phase 1b portion of the clinical trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of AVB-500 in combination with gemcitabine and nab-paclitaxel.

 

“We are pleased with the quick advancement of AVB-500 with the first patient dosed in our Phase 1b/2 pancreatic adenocarcinoma trial. This clinical trial addresses a very high unmet medical need in one of the most difficult-to-treat cancers with a high mortality rate,” said Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive. “We continue to expand the development of AVB-500, as the Company now has three ongoing clinical trials of AVB-500. In addition to the pancreatic adenocarcinoma clinical trial, AVB-500 is currently being investigated in a Phase 3 clinical trial for platinum resistant ovarian cancer and a Phase 1b/2 clinical trial for clear cell renal cell carcinoma.”

 

The Phase 1b/2 clinical trial is designed to evaluate AVB-500 as a first-line therapy in combination with gemcitabine and nab-paclitaxel (Abraxane®) in patients with advanced or metastatic pancreatic adenocarcinoma eligible to receive gemcitabine and nab-paclitaxel combination therapy. The Phase 1b portion of the clinical trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity in approximately 20 patients dosed with 15 mg/kg of AVB-500 in combination with gemcitabine and nab-paclitaxel. The randomized, controlled Phase 2 portion of the clinical trial is designed to evaluate approximately 60 patients dosed with 15 mg/kg of AVB-500 as a first-line therapy in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone. The primary endpoint of the Phase 2 portion of the trial is progression-free survival. The secondary endpoints are objective response rate, duration of response, clinical benefit rate, safety and overall survival, and the exploratory endpoints are pharmacokinetics and pharmacodynamics. The Phase 1b/2 trial is listed on clinicaltrials.gov NCT04983407.

 

About Pancreatic Cancer

Pancreatic cancer is the seventh leading cause of cancer death worldwide. There were approximately 495,800 new cases of pancreatic cancer and 466,000 deaths from the disease worldwide in 2020. It is estimated that there will be approximately 60,400 new cases of pancreatic cancer and 48,200 deaths from the disease in the U.S. in 2021. Pancreatic cancer typically has a poor prognosis, and the five-year survival rate is approximately 11%. Pancreatic adenocarcinoma is the most common type of pancreatic cancer, and there is a clear, high, unmet medical need to improve patient survival with new effective treatments that are safe and well-tolerated. Pancreatic cancer is projected to become the third leading cause of cancer death worldwide by 2025 and the second leading cause of cancer death in the U.S. by 2030.

 

About AVB-500

AVB-500 is a therapeutic recombinant fusion protein that has been shown to neutralize GAS6 activity by binding to GAS6 with very high affinity in preclinical models. In doing so, AVB-500 selectively inhibits the GAS6-AXL signaling pathway, which is upregulated in multiple cancer types including ovarian, renal and pancreatic cancer. In preclinical studies, GAS6-AXL inhibition has shown anti-tumor activity in combination with a variety of anticancer therapies, including radiation therapy, immuno-oncology agents, and chemotherapeutic drugs that affect DNA replication and repair. Increased expression of AXL and GAS6 in tumors has been correlated with poor prognosis and decreased survival and has been implicated in therapeutic resistance to conventional chemotherapeutics and targeted therapies. AVB-500 is currently being evaluated in multiple clinical trials and has been granted Fast Track Designation by the U.S. Food and Drug Administration in platinum resistant recurrent ovarian cancer. Analysis of all safety data to date showed that AVB-500 has been generally well tolerated with no dose-limiting toxicities or unexpected safety signals.

 

 

 

https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-logo.jpg

About Aravive

Aravive, Inc. is a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases. Aravive’s lead therapeutic, AVB-500, is a first-in-class ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth, tumor metastasis, resistance to treatment and decreased survival. AVB-500 has the potential to be combined with multiple anticancer therapies across several tumor types, due to its novel mechanism of action and favorable safety profile. AVB-500 has been granted Fast Track Designation by the U.S. Food and Drug Administration in platinum resistant recurrent ovarian cancer. The Company is currently evaluating AVB-500 in a registrational Phase 3 trial in platinum resistant ovarian cancer, a Phase 1b/2 trial in second line plus, clear cell renal cell carcinoma, and a Phase 1b/2 trial in first-line treatment of pancreatic adenocarcinoma. The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. For more information, please visit www.aravive.com.

 

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions and includes statements regarding the pancreatic cancer statistical data and the potential of AVB-500 to be combined with multiple anticancer therapies across several tumor types. Forward-looking statements are based on current beliefs and assumptions, are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those contained in any forward-looking statement as a result of various factors, including, but not limited to, risks and uncertainties related to: the ability to enroll the expected number of patients, the impact of COVID-19 on the Company's clinical strategy, clinical trials, supply chain and fundraising, the Company's ability to expand development into additional indications, the Company's dependence upon AVB-500, AVB-500's ability to have favorable results in clinical trials and ISTs, the clinical trials of AVB-500 having results that are as favorable as those of preclinical and clinical trials, the ability to receive regulatory approval, potential delays in the Company's clinical trials due to regulatory requirements or difficulty identifying qualified investigators or enrolling patients especially in light of the COVID-19 pandemic; the risk that AVB-500 may cause serious side effects or have properties that delay or prevent regulatory approval or limit its commercial potential; the risk that the Company may encounter difficulties in manufacturing AVB-500; if AVB-500 is approved, risks associated with its market acceptance, including pricing and reimbursement; potential difficulties enforcing the Company's intellectual property rights; the Company's reliance on its licensor of intellectual property and financing needs. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, recent Current Reports on Form 8-K and subsequent filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact:

Joseph T. Schepers

VP, Investor Relations, Aravive, Inc.

jschepers@aravive.com

(770) 558-5517

 
Image Exhibit

Exhibit 99.2

 

 

 

https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a01.jpg

 

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a02.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a03.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a04.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a05.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a06.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a07.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a08.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a09.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a10.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a11.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a12.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a13.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a14.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a15.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a16.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a17.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a18.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a19.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a20.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a21.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a22.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a23.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a24.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a25.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a26.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a27.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a28.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a29.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a30.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a31.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a32.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a33.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a34.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a35.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a36.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a37.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a38.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a39.jpg

 

 

 
https://cdn.kscope.io/edd713440c030d90fef8fb4afc761196-a40.jpg